News
-
Glenmark Pharmaceuticals announced that it has received FDA approval of its NDA for Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in patients aged 12 and older. The… Read more . . .
-
ReCode Therapeutics, which recently raised $80 million for development of inhaled genetic therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), has announced the appointment of former Theravance Biopharma executive Shehnaaz Suliman as CEO and… Read more . . .
-
Theravance Biopharma has announced the initiation of a Phase 4 study of Yupelri revefenacin inhalation solution, which was approved by the FDA in 2018 for the treatment of COPD. The PIFR-2 study, which is expected to… Read more . . .
-
RxPack, a new device company formed from a joint venture between Lindal and Coster in 2021, has announced the appointment of inhaler development specialist Alberto Colombo as Head of R&D and Customer Technical Support. Colombo… Read more . . .
-
According to Quantum Leap Healthcare Collaborative (QLHC), a sponsor of the I-SPY COVID trial, interim analysis of data from a study of Genentech’s Pulmozyme dornase alfa inhalation solution for the treatment of severe COVID-19 found that… Read more . . .
-
DPI developer PureIMS has announced the appointment of Jaap Wieling as Chief Executive Officer (CEO), succeeding Bram Van Dijck. According to his LinkedIn page, Wieling founded or co-founded several biopharm companies, including Bioralix, BiosanaPharma, and… Read more . . .
-
Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in… Read more . . .
-
Pfizer is paying Biohaven Pharmaceutical a total of $500 million upfront plus up to $740 million in potential milestone payments for the rights to market Biohaven’s rimegepant (Nurtec ODT) and zavegepant (BHV-3500) outside of the… Read more . . .
-
MannKind Corporation said that it has purchased an additional convertible note issued by Thirona Bio, and MannKind CEO Michael Castagna has joined the Thirona board of directors, extending a June 2021 deal between the two companies for… Read more . . .
-
Intranasal vaccine developer Intravacc and Leiden University Medical Center (LUMC) have announced a planned Phase 1/2 trial of LUMC’s Nanovac intranasal vaccine against coronaviruses, including SARS, MERS, and SARS-CoV-2. The trial is expected to begin… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.